替雷利珠单抗治疗晚期非小细胞肺癌患者的真实世界研究

AReal-worldStudyofTislelizumabinthe TreatmentofPatients with Advanced Non-small Cell Lung Cancer

HANHan，CHEN Yuchen，LIU Yang，RENFangfang，WANGXiyong （Oncology Department，Suzhou Hospitalof Anhui Medical University，Suzhou 234ooo，Anhui，China）

Abstract：Oeiveecndefbiatofdalllungl MethodsFromJanuaryO2OtoOctober2O23，patientswithadvancedNSCLCtreatedwithtislelzumabinSuzhouHospitalofAnhuiMedical UniverstyweredsiliicalacedsftisldKaaeerddfor survivalanalydCseoodlsdfelsulAotfatiseudn PFS was 5.43（95%CI 3.84-7.03）months，the medianOSwas12.17（95%CE7.72-16.62）months，andtheORRand DCR were 3 6 . 8 4 % and 6 6 . 3 2 % ， respectively.Kaplan-Meier univariate analysis showed that metastasis siteand ECOG score were related to PFS （ P<0 . 0 5 ） ，while metastasis site，ECOG score and treatment line number were related to OS（ .Multivariate analysis showed that intrapulmonary metastasis，distant metastasis，ECOG scoreandumberoftreamentlineswereindependentinfuencingfacorsofandintrapulmonarymelastasisECOGscoreadberf treatmentneepdtcorOeytlealdee reactionsignallsdldnli patients with advanced NSCLC.

Keyods：eballluttOallal free survival

国家癌症中心数据显示[1，肺癌在我国恶性肿瘤中的发病率和死亡率均居于首位，给人们带来沉重负担。（剩余9630字）